Portable, dual-energy X-ray detector delivers bone and tissue images in a single exposure.
The U.S. Food & Drug Administration (FDA) awarded 510(k) clearance to Ka Imaging, Inc., Monday for Reveal, its portable, dual-energy X-ray detector that, company officials, said can be used to slow the spread of COVID-19.
The detector differentiates itself by providing regular digital X-rays of bone and tissue in a single exposure, differentiating between the two without disruptions of other body parts that move during imaging, such as the heart. It is also designed for early detection of pneumonia, including COVID-19.
“What our dual energy X-ray imaging allows you to do is to produce in a single exposure of the lungs and ribs and look at them individually,” said Amol Karnick, Ka Imaging president and chief executive officer. “A good example is lung cancer where you may have a lesion or tumor hiding behind the rib cage. You remove the ribcage image and now you can see the lesion.”
In addition, Karnick said, Reveal also reduces radiation exposure and eliminates the quarter-to-half-second delay between separate exposures captured with existing dual energy X-ray imaging, eliminating potential image distortion.
Ka Imaging is testing the efficacy of its system in a 600-participant clinical trial at Toronto’s University of Health Network. The team is looking to determine how well it images lung disease, including pneumonia, as well as how effective it is in triaging COVID-19 infection prior to patients experiencing a drop in blood oxygen saturation. The trial will also compare thoracic tomograms to CT scans for early COVID-19 detection, and that data will be used to build an artificial intelligence model for automated and nearly instantaneous image interpretation, company officials said.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.